Zai Lab Ltd. ADR (ZLAB): Price and Financial Metrics

Zai Lab Ltd. ADR (ZLAB): $14.07

0.15 (-1.05%)

POWR Rating

Component Grades








Add ZLAB to Watchlist
Sign Up

Industry: China




#34 of 39

in industry

ZLAB Price/Volume Stats

Current price $14.07 52-week high $39.50
Prev. close $14.22 52-week low $13.48
Day low $13.93 Volume 465,900
Day high $14.23 Avg. volume 639,509
50-day MA $17.85 Dividend yield N/A
200-day MA $23.97 Market Cap 1.40B

ZLAB Stock Price Chart Interactive Chart >

Zai Lab Ltd. ADR (ZLAB) Company Bio

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in China and around the world. Our longer-term goal is to leverage our China-based competencies and resources to enable and impact human health worldwide. (Source:ZaiLaborator)

ZLAB Latest News Stream

Event/Time News Detail
Loading, please wait...

ZLAB Latest Social Stream

Loading social stream, please wait...

View Full ZLAB Social Stream

Latest ZLAB News From Around the Web

Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.

What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock

Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 22, 2023

Zai Lab Announces Participation in January Investor Conference

SHANGHAI & CAMBRIDGE, Mass., December 19, 2023--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024:

Yahoo | December 19, 2023

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List

BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia (CABP) and ac

Yahoo | December 13, 2023

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass., December 13, 2023--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications:

Yahoo | December 13, 2023

Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | December 7, 2023

Read More 'ZLAB' Stories Here

ZLAB Price Returns

1-mo -13.04%
3-mo -37.19%
6-mo -43.67%
1-year -60.92%
3-year -91.45%
5-year -53.50%
YTD -48.52%
2023 -10.98%
2022 -51.15%
2021 -53.56%
2020 225.41%
2019 79.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!